BR112023022735A2 - Derivado de fosfonila e composição e aplicação farmacêutica do mesmo - Google Patents

Derivado de fosfonila e composição e aplicação farmacêutica do mesmo

Info

Publication number
BR112023022735A2
BR112023022735A2 BR112023022735A BR112023022735A BR112023022735A2 BR 112023022735 A2 BR112023022735 A2 BR 112023022735A2 BR 112023022735 A BR112023022735 A BR 112023022735A BR 112023022735 A BR112023022735 A BR 112023022735A BR 112023022735 A2 BR112023022735 A2 BR 112023022735A2
Authority
BR
Brazil
Prior art keywords
phosphonyl
derivative
composition
pharmaceutical application
pharmaceutical
Prior art date
Application number
BR112023022735A
Other languages
English (en)
Inventor
Anbang Huang
Chen Zhang
Chenfei Zhao
Fei Ye
Guofei Qian
Jia Ni
Jianmin Wang
Junjie Ma
Kai Li
Pangke Yan
Pingming Tang
Shaolong Zheng
Shuai Yuan
Yan Yu
Yao Li
Zhenggang Huang
Original Assignee
Xizang Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xizang Haisco Pharmaceutical Co Ltd filed Critical Xizang Haisco Pharmaceutical Co Ltd
Publication of BR112023022735A2 publication Critical patent/BR112023022735A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

derivado de fosfonila e composição e aplicação farmacêutica do mesmo. são fornecidos o composto mostrado na fórmula geral (i) ou um estereoisômero, um composto deuterado, um solvato, um pró-fármaco, um metabólito, um sal farmaceuticamente aceitável ou cocristal do mesmo, um intermediário do mesmo, e um uso do mesmo em doenças relacionadas ao egfr, como câncer. b-l-k (i).
BR112023022735A 2021-04-30 2022-04-29 Derivado de fosfonila e composição e aplicação farmacêutica do mesmo BR112023022735A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202110470748 2021-04-30
CN202110570092 2021-05-25
CN202110651028 2021-06-11
CN202110824204 2021-07-22
CN202111025788 2021-09-03
CN202111214457 2021-10-22
CN202210000254 2022-01-06
PCT/CN2022/090243 WO2022228547A1 (zh) 2021-04-30 2022-04-29 一种膦酰衍生物及其组合物和药学上的应用

Publications (1)

Publication Number Publication Date
BR112023022735A2 true BR112023022735A2 (pt) 2024-01-02

Family

ID=83847797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022735A BR112023022735A2 (pt) 2021-04-30 2022-04-29 Derivado de fosfonila e composição e aplicação farmacêutica do mesmo

Country Status (14)

Country Link
US (1) US20240269298A1 (pt)
EP (1) EP4332100A1 (pt)
JP (1) JP2024518363A (pt)
KR (1) KR20240005838A (pt)
CN (1) CN117425646A (pt)
AU (1) AU2022263747A1 (pt)
BR (1) BR112023022735A2 (pt)
CA (1) CA3217325A1 (pt)
CL (1) CL2023003223A1 (pt)
IL (1) IL308103A (pt)
MX (1) MX2023012743A (pt)
TW (1) TW202308655A (pt)
WO (1) WO2022228547A1 (pt)
ZA (1) ZA202311035B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240109270A (ko) * 2021-11-17 2024-07-10 티와이케이 메디슨즈, 인코포레이티드 Egfr 단백질 분해용 화합물 및 이의 용도
TW202415655A (zh) 2022-06-13 2024-04-16 美商樹線生物科學公司 １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑
WO2024032600A1 (zh) * 2022-08-08 2024-02-15 西藏海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
TW202428573A (zh) * 2022-10-20 2024-07-16 大陸商西藏海思科製藥有限公司 膦醯衍生物的鹽及晶型和在醫藥上的用途
WO2024188209A1 (zh) * 2023-03-10 2024-09-19 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102538307B1 (ko) * 2017-12-13 2023-05-31 상하이테크 유니버시티 Alk 단백질 분해제 및 암 치료에서의 이의 용도
WO2019196812A1 (zh) * 2018-04-09 2019-10-17 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
CN111285849A (zh) * 2018-12-07 2020-06-16 上海青东生物科技有限公司 一种靶向降解ALK，c-Met和ROS1蛋白的化合物及其制备方法
CA3126976A1 (en) 2019-01-18 2020-07-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salt of egfr inhibitor, crystal form, and preparation method therefor
JP7426124B2 (ja) * 2019-06-12 2024-02-01 シャンハイテック ユニバーシティ Ａｌｋタンパク質レギュレーター、及びその抗腫瘍における使用
JP2022546375A (ja) * 2019-08-23 2022-11-04 北京泰徳製薬股▲フン▼有限公司 Ｅｇｆｒおよびａｌｋを阻害してそれらの分解を阻害する化合物
EP4110340A4 (en) * 2020-02-25 2024-08-28 Dana Farber Cancer Inst Inc POTENT AND SELECTIVE ALK DEGRADING AGENTS
US20230248834A1 (en) * 2020-07-16 2023-08-10 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
CN116323580A (zh) * 2020-07-16 2023-06-23 百济神州有限公司 通过egfr抑制剂与e3连接酶配体的缀合降解(egfr)和使用方法

Also Published As

Publication number Publication date
TW202308655A (zh) 2023-03-01
JP2024518363A (ja) 2024-05-01
IL308103A (en) 2023-12-01
CN117425646A (zh) 2024-01-19
KR20240005838A (ko) 2024-01-12
US20240269298A1 (en) 2024-08-15
AU2022263747A1 (en) 2023-12-14
EP4332100A1 (en) 2024-03-06
WO2022228547A1 (zh) 2022-11-03
MX2023012743A (es) 2023-11-09
ZA202311035B (en) 2024-07-31
CA3217325A1 (en) 2022-11-03
CL2023003223A1 (es) 2024-05-10

Similar Documents

Publication Publication Date Title
BR112023022735A2 (pt) Derivado de fosfonila e composição e aplicação farmacêutica do mesmo
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
BR112023018785A2 (pt) Composto cíclico fundido com pirimidina, método de preparação do mesmo e uso do mesmo
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112021022897A2 (pt) Inibidor contendo derivado bicíclico, método de preparação do mesmo e uso do mesmo
BR112018006025A2 (pt) composição farmacêutica e aplicação da mesma
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
BR112021011325A2 (pt) Derivados de rapamicina
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
BR112012030621A8 (pt) Compostos para o tratamento de doença associada a clostridium difficile
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma